Community Education Webinars

In partnership with The ALS Association, NEALS offers a variety of educational webinars for the ALS community.

Webinar topics include updates on clinical trials, best practices for clinical care, and current research efforts in ALS causes and treatments. Our webinars also offer participants the opportunity to ask questions directly of the experts running clinical trials and conducting research activities.

June 17, 2022 / 5:00 pm-6:00 pm

Healey ALS Platform Trial Regimen E: A Participant’s Guide

Presenters: Dr. Merit Cudkowicz (Sean M. Healey & AMG Center for ALS at Mass General Hospital), Dr. Sabrina Paganoni (Sean M. Healey & AMG Center for ALS at Mass General Hospital), and Dr. Shafeeq Ladha (Barrow Neurological…

May 6, 2022 / 10:30 am-11:30 pm

A Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD

The purpose of this webinar is to provide an overview of a new clinical study for people living with ALS and a mutation in the C9orf72 gene. We will describe the scientific rationale for the study, the investigational drug (TPN-101),…

March 18, 2022 / 12:00 pm-1:00 pm

The Latest on Expanded Access Protocols in ALS

Please join us for a conversation about Expanded Access Protocols (EAPs) in ALS, including recent progress in setting EAPs up alongside clinical trials. This webinar will be moderated by Dr. Jinsy Andrews and will feature Dr. Merit…

March 17, 2022 / 2:00 pm-2:30 pm

The ATLAS Study: A Clinical Trial for Adults with a Confirmed Superoxide Dismutase 1 (SOD1) Mutation without Signs or Symptoms of Amyotrophic Lateral Sclerosis (ALS)

A Clinical Trial for Adults with a Confirmed Superoxide Dismutase 1 (SOD1) Mutation without Signs or Symptoms of Amyotrophic Lateral Sclerosis (ALS)The purpose of this webinar is to provide an overview of the ATLAS study, the…

February 24, 2022 / 3:00 pm-4:00 pm

Phase 2a trial of Oral LAM-002A capsules in C9ORF72 ALS

Please join us on February 24th for a webinar to learn about a new Phase 2a trial of Oral LAM-002A capsules for individuals with C9ORF72 positive ALS.

December 14, 2021 / 1:00 pm-2:00 pm

Courage ALS, a Phase 3 Trial of Reldesemtiv in ALS

Please join us to learn about COURAGE-ALS, a global phase 3 trial of reldesemtiv currently enrolling participants.

September 23, 2021 / 1:00 pm-2:00 pm

An Update on AMX0035 and Design of the Phase 3 PHOENIX Study

Please join Dr. Merit Cudkowicz, MD, MSc (Sean M. Healey & AMG Center for ALS at Mass General Hospital) and Dr. Sabrina Paganoni, MD, PhD (Sean M. Healey & AMG Center for ALS at Mass General Hospital) for a…

September 15, 2021 / 4:00 pm-5:00 pm

ALS Drug Development Webinar Series Part 6: Research Engagement by People Living With ALS

In this webinar, Dr. Richard Bedlack (Duke ALS Clinic) and Dr. Merit Cudkowicz (Sean M. Healey & AMG Center for ALS at Mass General Hospital) will discuss why research engagement by people living with ALS is important, examples of…

August 18, 2021 / 4:00 pm-5:00 pm

ALS Drug Development Webinar Series Part 5: Preclinical Development of Potential Therapies

The fifth installment of the NEALS webinar series on ALS drug development moderated by Dr. Richard Bedlack from Duke ALS Clinic. This series includes talks on the preclinical development of potential therapies, the regulatory pathway,…

July 13, 2021 / 1:00 pm-2:00 pm

Moving research forward using Answer ALS resources

Join Dr. Steven Zeiler, Dr. Terri Thompson and Ed Rapp on July 13th to hear more about the newly launched ALS Companion app and the Answer ALS data portal. Answer ALS is creating a hub of ALS knowledge and resources to help propel…